Patent · US Active

Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

US11266724B2 · kind B2 · utility

0Cited by

51References

17Claims

0Family size

Assignee

Catalyst Biosciences, Inc. · US

Inventors

Grant E. BLOUSE · Burlingame, US
Tom KNUDSEN · Burlingame, US
Howard Levy · Cedar Park, US

Key dates

Filing date	Feb 19, 2021
Grant date	Mar 8, 2022
Priority date	—
Expiry date	Feb 19, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are modified FVII polypetides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.